MGMA 2021: IRIS Solution Spotlight

diabetic retinopathy


Diabetic Retinopathy (DR) is the leading cause of blindness in all U.S. adults, although it is totally preventable if diagnosed before disease progression during yearly eye exams. Still, of 34 million Americans diagnosed with diabetes, only 30% follow through with their annual eye exams.

Join Linda Dorrel, IRIS sales director, as she discusses diabetic retinopathy and the IRIS solution in the MGMA 2021 Solution Spotlight.

Doctor’s visits, for many, equal inconvenience; however, when it comes to DR, the difference between taking an exam and skipping one can be worlds apart. That is why IRIS strives to make screening accessible and convenient for both healthcare providers and their patients. 

IRIS’ expert team works with clients around the clock to ensure streamlined and successful program implementation. Alongside PrismaHealth, IRIS has already saved 106,000 patients with sight-threatening eye disease, and that number continues to grow across our many partners. Find out how IRIS can effortlessly integrate with your organization to increase screening compliance and stop Diabetic Retinopathy. 

Connect with us to learn more about how IRIS can work in your practice today.

Get started with IRIS today.

Want to know if IRIS is right for you? Schedule a one-on-one consultation with our team. We’re here to help.